Latest News About Vitamin K Deficiency

Here are the latest developments on vitamin K deficiency as of 2025–2026.

• Neonatal vitamin K deficiency bleeding (VKDB) remains a key prevention focus. Several reviews and guidelines reaffirm that a vitamin K shot at birth dramatically reduces risk, with oral regimens as an alternative only when intramuscular administration is declined, and with careful follow-up to cover late-onset VKDB. This is supported by recent case reviews and guideline summaries.[1][2][4]

• Recent emphasis on caregiver refusal of intramuscular vitamin K at birth has coincided with renewed attention to late-onset VKDB, including multi-system complications in rare cases. Health organizations continue to advocate for universal parenteral prophylaxis, while acknowledging oral regimens as a secondary option if IM administration is refused.[1]

• VKDB prevention in high-income and emerging health systems often centers on reinforcing birth protocols and parental counseling. Contemporary reviews note that intramuscular vitamin K is more effective than oral dosing for comprehensive protection, though oral regimens can be used with a structured dosing plan when IM is not possible.[2]

• Broader vitamin K deficiency literature covers adults and chronic disease implications, including roles in bone and cardiovascular health, but the most urgent current news relates to VKDB prevention and management in newborns. General reviews summarize VKD as a potential cause of coagulopathy across ages and emphasize prevention strategies and treatment options when deficiency occurs.[6][9]

• Treatment for suspected VKDB remains rapid administration of parenteral vitamin K, with adjunctive therapies (e.g., plasma products) for severe bleeding, and ongoing education for families and caregivers about the importance of vitamin K prophylaxis.[9][1]

Illustrative example:

• A 2024 case report highlights how timely intramuscular vitamin K corrected coagulopathy within hours in a newborn, while noting rising VKDB risk when IM prophylaxis is refused and the need for careful follow-up if oral strategies are used.[1]

If you’d like, I can pull the latest official guidelines (e.g., from CDC, NICE, AAP) and summarize their recommendations side-by-side, or focus on VKDB in neonates only, with a quick Q&A on prevention and management. I can also provide recent research abstracts or patient-friendly explanations. Please tell me your preferred focus and format.

Citations:

• VKDB prevention and IM vs oral vitamin K strategies[1]
• Neonatal VKDB guidelines and oral regimens context[2]
• VKDB prevention policy and newborn prophylaxis discussions[4]
• Comprehensive VKD overview and clinical management[6]
• VKD diagnosis and management overview[9]